Pfizer profit and loss

Latest FY26

Revenue: ₹2,520cr+10.4% on FY25
EBITDA: ₹904cr+22.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,570	2,520	2,281	2,193	2,425	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	166	—	172	—	101
	2,735	2,708	2,454	2,374	2,526
	326	310	272	336	345
	667	608	513	469	472
	−79.7	−33.6	25.4	−11.8	56.5
	354	368	371	348	332
	7.7	9.5	8.4	15.4	13.4
	57.6	57.7	60.8	62.3	106
	361	—	359	—	411
	1,693	1,683	1,610	1,636	1,735
	942	904	740	635	809
	884	846	679	573	703
Profit
	1,042	1,025	843	738	791
	−49.2	—	—	—	—
	993	976	1,016	746	824
	261	258	264	159	252
	−3.4	—	—	—	−51.9
	258	—	—	—	200
	735	722	768	551	624
	735	—	—	—	—
	4.2	—	—	—	3.6
	739	726	768	557	628
Per share
	₹160.70	—	—	—	—
	₹119.38	—	—	—	—
Other comprehensive income — detail
	4.2	—	—	—	—
	−0.2	—	—	—	—
	0.3	—	—	—	—
Per share — as-filed variants
	₹160.70	—	—	—	—
	₹119.38	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,657	1,635	1,471	1,401	1,551
	64.5%	64.9%	64.5%	63.9%	64.0%
Adjusted (ex-exceptional items) — derived
	1,042	1,025	843	738	791
	−49.2	—	—	—	—
	772	759	638	545	599
	₹168.66	—	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersGLAXO ABBOTINDIA POLYMED ONESOURCE RAINBOW KIMS JUBLPHARMA VIJAYA

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,424.8	2,193.2	2,281.4	2,519.7	2,569.8
Other Income	101.1	—	172.3	—	165.6
Total Income	2,525.8	2,373.7	2,453.6	2,707.6	2,735.4
Expenses
+ Cost of Materials Consumed	345.3	335.8	272.3	309.5	325.8
+ Purchases of Stock-in-Trade	471.9	468.6	512.8	608.4	667.0
+ Changes in Inventories	56.5	-11.8	25.4	-33.6	-79.7
+ Employee Benefit Expense	331.7	347.8	371.3	368.0	354.2
+ Finance Costs	13.4	15.4	8.4	9.5	7.7
+ Depreciation & Amortisation	105.5	62.3	60.8	57.7	57.6
+ Other Expenses	410.6	—	359.3	—	360.7
Total Expenses	1,734.8	1,635.6	1,610.3	1,682.8	1,693.4
EBITDA	808.9	635.3	740.2	904.1	941.6
EBIT	703.4	573.0	679.4	846.4	884.1
Profit
PBT before Exceptional Items	791.0	738.1	843.3	1,024.8	1,042.0
+ Exceptional Items	—	—	—	—	-49.2
Pretax Income	824.0	746.1	1,016.1	975.7	992.8
+ Current Tax	251.8	158.9	264.1	257.5	261.1
+ Deferred Tax	-51.9	—	—	—	-3.4
Tax Expense	199.9	—	—	—	257.7
Net Income	623.9	551.3	767.6	722.4	735.2
+ Net Income — Continuing Ops	—	—	—	—	735.2
+ Other Comprehensive Income	3.6	—	—	—	4.2
Total Comprehensive Income	627.5	556.8	768.3	726.3	739.4
Per Share
Basic EPS	—	—	—	—	160.70
Diluted EPS	—	—	—	—	119.38
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	4.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	-0.2
+ Tax on Items to be Reclassified	—	—	—	—	0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	—	—	—	160.70
Diluted EPS — Continuing Operations	—	—	—	—	119.38
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,551.1	1,400.6	1,470.9	1,635.3	1,656.6
Gross Margin %	63.97	63.86	64.47	64.90	64.46
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	791.0	738.1	843.3	1,024.8	1,042.0
− Exceptional Items (reconciliation)	—	—	—	—	-49.2
Net Income Adj (tax-effected)	598.9	545.4	638.0	759.3	771.6
EPS Adj	—	—	—	—	168.66
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	—	—	—	10.00
Paid Up Equity Capital	—	—	—	—	45.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.